Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Time for a new uptick, running leg Up

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Oct 12, 2021 5:00pm

242 Views

Post# 33998810

RE:Time for a new uptick, running leg Up

canadafan wrote:
I do follow price & trading action.
it was posted either this site or another, that many of the BOD , bought some shares last week.
That usually precludes a new uptrend.
I bought a few more last week.
Q4 news " expected milestones" , only have 2.5 months left.
imho we are now on a slow recovery path in the price.
Any news, in realm of recent very low volumes, will move the price considerably.

[/quote

Just pulled this off of Yahoo. Says last 6 month. Don't know if there is a couple week delay in posting Insider info to Yahoo, but this would suggest only 3 insiders bought in June 2021.

I am curious as to where else you might have read something different ?

Thanks

Insider Transactions

Currency in CAD

Insider Purchases Last 6 Months	Shares	Trans
Purchases	0	0
Sales	N/A	0
Net Shares Purchased (Sold)	0	0
Total Insider Shares Held	718.87k	N/A
% Net Shares Purchased (Sold)	0.00%	N/A

Net Institutional Purchases Prior Quarter to Latest Quarter	Shares
Net Shares Purchased (Sold)	N/A
% Change in Institutional Shares Held	N/A

Insider Transactions Reported - Last Two Years

Insider	Transaction	Type	Value	Date	Shares
SEIZINGER (BERND R.) Director of Issuer		Direct		Jun 30, 2021	6,101
PISANO (WAYNE) Director of Issuer		Direct		Jun 30, 2021	5,033
HOLTHAM, ANGELA FRANCES Director of Issuer	Acquisition or disposition in the public market at price 2.77 per share.	Indirect	6,400	Jun 30, 2021	2,313
HOLTHAM, ANGELA FRANCES Director of Issuer	Acquisition or disposition in the public market at price 2.97 per share.	Direct	20,797	Jun 07, 2021	7,000
PISANO (WAYNE) Director of Issuer		Direct